Compare AstraZeneca plc (AZN) vs Flagstar Bank NA (FLG) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

Flagstar Bank (FLG) trades at $14.88, down 1.39% today, with a bullish technical outlook supported by moving averages. The stock shows improving fundamentals with two consecutive quarterly EPS beats and a positive Q1 2026 net income of $0.04 per share. Recent news highlights management's focus on technology transformation and balance sheet stabilization, while the P/B ratio of 0.82 indicates potential undervaluation relative to book value.

The outlook is cautiously optimistic with a consensus price target of $17.05 offering 14.6% upside. Risks include negative net income margins and high interest expenses, but analyst sentiment is positive with no sell ratings. The upcoming Q2 2026 earnings report on July 24, 2026, will be critical for confirming the turnaround trajectory.